Kyntra Bio, Inc. (KYNB)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
The Discovery, Development and Commercialization of Novel Therapeutics	29.62M	46.80M	140.73M	235.31M	176.32M
The Discovery, Development and Commercialization of Novel Therapeutics Growth	-36.71%	-66.74%	-40.19%	33.46%	-31.28%
Total	29.62M	46.80M	140.73M	235.31M	176.32M
Total Growth	-36.71%	-66.74%	-40.19%	33.46%	-31.28%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
United States	26.11M	12.96M	12.52M	46.12M	65.18M
United States Growth	101.48%	3.53%	-72.86%	-29.24%	-42.39%
Europe	6.27M	9.55M	33.82M	131.24M	17.95M
Europe Growth	-34.34%	-71.77%	-74.23%	631.00%	-87.67%
Japan	-2.85M	15.87M	9.76M	2.31M	19.82M
Japan Growth	-	62.51%	323.60%	-88.37%	-
China	91.00K	8.43M	84.63M	55.64M	73.36M
China Growth	-98.92%	-90.04%	52.10%	-24.16%	249.89%
Total	29.62M	46.80M	140.73M	235.31M	176.32M
Total Growth	-36.71%	-66.74%	-40.19%	33.46%	-31.28%

Source: S&P Global Market Intelligence.